Lirilumab
Phase 2Monoclonal antibody
Bristol-Myers SquibbLirilumab is one of 35 small molecule programs targeting Pediatric Cancer. It is currently in Phase 2.
2
Indications
11
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
28 competitors in Pediatric Cancer
#DrugCompanyPhaseTrials
1Trisenox
CCephalon
Phase 2
Cytosar
TevaPhase 1
Bavencio
EMD SeronoPhase 1
Zanzalintinib
Merck & Co.Phase 1
M6620
AstraZenecaPreclinical
Imfinzi
AstraZenecaPreclinical
Kisqali
NovartisPreclinical
Afinitor
NovartisPreclinical
Adavosertib
AstraZenecaPreclinical
Lynparza
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma2 trials
Acute Myeloid Leukemia1 trial
Malignancies1 trial
5 more indications
Advanced1 trial
Nivolumab1 trial
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
Active, not recruiting·—·Phase 2·NCT03341936·29 enrolled
Metastatic Solid Tumors1 trial
Chronic Lymphocytic Leukemia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lirilumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company